Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ivax CFC-Free Albuterol Will Launch In Fourth Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA cleared the NDA for the asthma treatment Oct. 29. Ivax’ CFC-free albuterol inhaler offers an alternative to GlaxoSmithKline’s Ventolin HFA in advance of an FDA final rule that is expected to remove CFC-propelled albuterol from the market in 2006.

You may also be interested in...



Atrovent HFA Approval Breathes New Life Into Boehringer Ingelheim's Brand

The CFC-free version of the bronchodilator will receive three years of labeling exclusivity. FDA action to move ozone-depleting products off the market could remove BI's generic Atrovent competition.

Atrovent HFA Approval Breathes New Life Into Boehringer Ingelheim's Brand

The CFC-free version of the bronchodilator will receive three years of labeling exclusivity. FDA action to move ozone-depleting products off the market could remove BI's generic Atrovent competition.

Ivax Breath-Activated HFA Albuterol Is “Approvable”

Ivax' breath-activated hydrofluoroalkane-propelled albuterol is "approvable" at FDA, the company announced July 7

Related Content

Topics

UsernamePublicRestriction

Register

LL1133060

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel